Share Name Share Symbol Market Type Share ISIN Share Description
Valirx LSE:VAL London Ordinary Share GB00BWWYSP41 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 3.75p 3.50p 4.00p 3.75p 3.75p 3.75p 148,772.00 07:30:07
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.1 -2.6 -6.7 - 2.88

Valirx Share Discussion Threads

Showing 18551 to 18572 of 18575 messages
Chat Pages: 743  742  741  740  739  738  737  736  735  734  733  732  Older
DateSubjectAuthorDiscuss
27/2/2017
09:21
Few takers even at these prices..??? Today 10:04 Price: 3.75 MrBB 1,022 posts Aberiterone/Zytiga If Johnson & Johnson, or BTG considered 201 to be a thread to their position, (with revenue to JJ of about $1 bill & royalties to BTG in excess of $30mill ) , surely they would eith acquire 201 or the whole of Val, for a relatively modest amount in order to either shelve it or develope it to work in conjunction . Their apparent lack of interest suggests that that they do not see 201 as any type of threat to their position. Off Topic No Opinion
thebossman
26/2/2017
20:32
Could it be a forthcoming CLN conversion? YA or Bracknor perhaps?
vatnabrekk
26/2/2017
19:15
looks a bit cheap for someone who is making drugs for something like prostate cancer. Are the board lying?
neo26
26/2/2017
18:25
Http://www.berkshirehathaway.com/letters/2016ltr.pdf
spob
26/2/2017
17:58
neo..you tell me after you have read all the relevant stuff,I'm as just in the dark has everyone else associated with this but our share price tells another story..
thebossman
26/2/2017
17:33
"....ValiRx is entering a very exciting phase, which should result in the crystallisation of substantial value".This was in Jan so what has changed?
neo26
26/2/2017
17:32
Bossman which RNs, last RNs was 11 Jan...
neo26
26/2/2017
16:03
neo..read the RNS and you will know its that simple,also drop GM an email he might have an answer for you too..But don't hold your breath..
thebossman
26/2/2017
12:26
What happened to this company?Do they need more cash?Its on ridiculous levels.
neo26
25/2/2017
16:12
Will creep back up again next week.
y1phr1
25/2/2017
13:07
Bobby..if that's the case then why are we still trading then ..???
thebossman
24/2/2017
18:30
What a week.
teamhanz1
24/2/2017
17:09
I think you should also look at the emperors clothes errrr I mean 201 and 401 ;-) remember this is AIM ! ! ! ! ! maxmarilli 23 Feb '17 - 22:51 - 5088 of 5095 301?the missing compound? thebossman 24 Feb '17 - 08:19 - 5089 of 5095 Max..it did not go missing, maybe it was never there in the first place.
cautiousmoney
24/2/2017
16:41
Two times 150,000 sells again at end of day same as yesterday
y1phr1
24/2/2017
14:31
as you say,bossman,either there is something/someone that is interested in getting it as low as possible(probably to launch a bid)or all these good reports don`t make up....this is valued 99% LESS than when it started!
maxmarilli
24/2/2017
14:17
Annual Report and Accounts 2015 ValiRx plc..For all to see and from the horses mouth...So why the decline in our share price ..?? summary... Lung Cancer and others VAL401 is the reformulation of a generic drug that has over 20 years of clinical use for treatment of a chronic non-oncology disease in an oral capsule. The re-formulation allows the drug to access previously unexploited anti-cancer activity. VAL401 is progressing satisfactorily through its remaining preclinical development and towards clinical Phase II trials for the treatment of lung cancer and other oncology indications. Progress into clinical trials will comprise a shorter than usual route to Market Authorisation by use of prior clinical data gathered on the original generic drug. Preclinical efficacy data has been collected in both non-small cell lung and prostate cancers. Preclinical toxicology has revealed no side effects beyond those expected from the parent drug, with preclinical pharmacokinetc data allowing bridging from VAL401 to the historical full clinical data package on the parent. Formulation stability tests are currently underway to complete the CMC package....... During 20 years of prior clinical use, the active drug has been safely administered long term (chronic use of over 2 year’s duration) with good compliance. Indications Other possible indications include.... prostate and pancreatic cancer. “I am delighted that VAL401 has progressed according to schedule since being in-licensed to the ValiRx group last year. We look forward to hearing reports from ValiSeek of further advancement over the coming year.” Dr Satu Vainikka Chief Executive Officer FTO JG...Outlook In conclusion, the period under review has been pleasingly satisfactory and our teams around the VAL201 and VAL401 compounds have started talking to parties for late stage clinical studies and for potential partnerships and collaboration with pharmaceutical partners. ValiRx continues to look to expand its Intellectual Property (“IP”) as its development programmes go forward and it remains open to technology acquisition opportunities and ways in which it can both deliver and grow shareholder value. hTTp://1cqi8a4dpf4p8okqjp35hmi5.wpengine.netdna-cdn.com/wp-content/uploads/2016/05/ValiRx_Annual-Report_2015_Hyperlink.pdf
thebossman
24/2/2017
09:37
ValiRx PLC, VAL:LSE financials - FT.com https://markets.ft.com/data/equities/tearsheet/financials?s=VAL... Traducir esta página ValiRx PLC (VAL:LSE) financials, including income statements, growth rates, balance sheets and cash ... ValiRx PLC uses little or no debt in its capital structure. Iv taken everything into account and logic dictates something is very fishy when we have had no bad news with the trials etc etc,when we consolidated we started a [email protected] more important we have no debt i believe as such.....quote“When you eliminate the impossible, whatever remains, however improbable, must be the truth.”
thebossman
24/2/2017
09:16
You haven't taken into account the highly dillutive wonga style funding spiral of death. I've written this share off, live and learn. Until bracknor are out and warrants disposed of this is going to continue to be strangled to death. The Bod have probably woken up to the fact that they screwed up big time with the wonga funding and have stuck their heads in the sand over it.
o0timbo0o
24/2/2017
09:11
it also makes no sense the share price would be dragged this low if has our BOD are saying we have news soon that will move the share price to where it was at 50p+...This would make the MMs look very foolish unless they know different..Aimo
thebossman
24/2/2017
08:19
Max..it did not go missing, maybe it was never there in the first place.
thebossman
23/2/2017
22:51
301?the missing compound?
maxmarilli
23/2/2017
20:01
More stronger words are needed from you JG especially with the amount of dosh you say you have invested in valirx.. Today 19:43 Price: 4.00 johngilchrist 6,932 posts RE: Top Up No i'm not exactly thrilled with their performance. They have failed to deliver a commercial deal, and the salesman seemed to get sacked for that. I don't think that they had that much control of the really weak funding environment on AIM, and the lack of interest from institutional investors. A key failure seems in PR and marketing, and the lack of attracting any independent valuation via broker notes. Currently the company is being valued based on the past performance of a 2 year chart, and that isn't very appealing. Looking forward there should be plenty of trial news ahead on 201, 401 and 301. But concerns on forward funding continue to haunt us.
thebossman
Chat Pages: 743  742  741  740  739  738  737  736  735  734  733  732  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20170227 11:24:43